Technical Analysis for DMAC - DiaMedica Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 2.89 -2.03% -0.06
DMAC closed down 2.03 percent on Friday, September 13, 2019, on 43 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical DMAC trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Support Bullish -2.03%
Outside Day Range Expansion -2.03%
Wide Bands Range Expansion -2.03%
Narrow Range Bar Range Contraction 7.04%
Wide Bands Range Expansion 7.04%
Down 3 Days in a Row Weakness 7.04%
Down 4 Days in a Row Weakness 7.04%
Narrow Range Bar Range Contraction 3.96%

Older signals for DMAC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
DMAC Chart by TradingView
Basic chart:
Profile
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Kidney Diseases Ischemia
Is DMAC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 11 DiaMedica Therapeutics (DMAC) Presents At 4th Annual Dougherty & Company Institutional Investor Conference - Slideshow
Sep 6 DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
Sep 3 DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
Aug 15 Sintx Technologies leads healthcare gainers; Cytosorbents and Genetic Technologies among losers
Aug 15 The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings
Aug 15 61 Biggest Movers From Yesterday
Aug 14 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2019 Results - Earnings Call Transcript
Aug 14 Novavax and Akari Therapeutics among healthcare gainers; DelMar Pharmaceuticals leads the losers
Aug 13 DiaMedica Therapeutics EPS beats by $0.05
Aug 13 DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
See more DMAC news...
Indicators
Indicator Value
52 Week High 6.53
52 Week Low 0.2588
Average Volume 50,888
200-Day Moving Average 3.5537
50-Day Moving Average 3.3018
20-Day Moving Average 2.7135
10-Day Moving Average 2.883
Average True Range 0.2612
ADX 27.23
+DI 17.5248
-DI 21.0194
Chandelier Exit (Long, 3 ATRs ) 2.3264
Chandelier Exit (Short, 3 ATRs ) 2.9336
Upper Bollinger Band 3.13
Lower Bollinger Band 2.297
Percent B (%b) 0.71
BandWidth 30.69836
MACD Line -0.0869
MACD Signal Line -0.1439
MACD Histogram 0.057
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.11
Resistance 3 (R3) 3.12 3.05 3.08
Resistance 2 (R2) 3.05 2.99 3.05 3.06
Resistance 1 (R1) 2.97 2.96 3.01 2.96 3.05
Pivot Point 2.90 2.90 2.92 2.90 2.90
Support 1 (S1) 2.82 2.84 2.86 2.82 2.73
Support 2 (S2) 2.75 2.81 2.75 2.72
Support 3 (S3) 2.67 2.75 2.70
Support 4 (S4) 2.67